Clinically, there have been many breakthroughs in LAG-3-targeted therapies in recent years; for example, the newly approved LAG-3 immune checkpoint inhibitor Relatlimab plus the PD-1 inhibitor Nivolumab [37,38] for melanoma treatment, can more than double the survival rate and reduce treatment side effects versus nivolumab alone. This evidence concerns the gene LAG3 and melanoma.